HomeNew HDAC Inhibitors

New HDAC Inhibitors

Catalog No. Product Name Information
E8178 Quisinostat Quisinostat(JNJ-26481585) is a potent and orally active second-generation inhibitor of pan-Histone Deacetylase (HDAC). It inhibits HDAC1, HDAC2, HDAC4, HDAC10, HDAC11 with IC50s of 0.11 nM , 0.33 nM , 0.64 nM , 0.46 nM, 0.37 nM respectively. It exhibits potent in vivo antitumor activity and potential clinical use in various solid and hematologic malignancies.
E0391 BRD-6929 BRD-6929 is an inhibitor of histone deacetylase 1 (HDAC1) and HDAC2 with an IC50s of 0.04 µM and 0.1 µM, respectively. It exhibits antiproliferative activities against a human cancer cell line (HCT116) and in human mammary epithelial cells (HMEC).
E1686 SW-100 SW-100 is a selective inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 2.3 nM. It displays 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes.
E1580 TNG260 TNG260 is an inhibitor of CoREST-selective deacetylase (CoreDAC) that inhibits HDAC1 with 10-fold selectivity over HDAC3. It decreases intratumoral neutrophil infiltration and exhibits immune-mediated cell killing.
E1912 B102(PARP/HDAC-IN-1) B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro.
≡ All HDAC Inhibitors